Anti-diabetic drug dispute leads to ICC award

The biopharmaceuticals arm of Merck has secured damages from a French spin-off company in an ICC arbitration over royalties owed under agreements to develop an anti-diabetic drug.


Get unlimited access to all Global Arbitration Review content